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ABSTRACT
The aim of this study was to evaluate the effect of GB virus C on laboratory markers and histological parameters among HIV-seropositive patients 
coinfected with HCV. Lower degrees of hepatic lesions were observed in the triple-infected patients, in comparison with HIV-HCV coinfected patients 
who were negative for GBV-C RNA.
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RESUMO
O objetivo do estudo foi avaliar o efeito da infecção pelo vírus GB-C em marcadores laboratoriais e parâmetros histológicos em pacientes HIV 
soropositivos coinfectados com VHC. Menor grau de lesão hepática foi observado nos pacientes com tripla infecção em comparação aos pacientes 
coinfectados com VIH-VHC negativos para GBV-C RNA.
Palavras-chaves: Vírus GB-C. Vírus da hepatite G. Vírus da hepatite C. VIH. Coinfecção.
GB virus C (GBV-C) is a flavivirus closely related to hepatitis C 
virus (HCV), with amino acid sequence homology of approximately 
30%7. GBV-C14 and hepatitis G virus (HGV)8 are independent 
isolates of the same RNA virus. GBV-C was initially reported 
to be associated with post-transfusion hepatitis in humans8. 
However, several research groups demonstrated there was no 
evidence of associations between GBV-C infection and hepatitis1. 
The liver-specific pathogenicity and tropism of GBV-C remain 
to be clarified. While some research groups found the GBV-C 
genome in hepatocytes13, other groups reported that GBV-C is 
not hepatotropic6 10. In vitro studies have shown that GBV-C is 
able to infect peripheral blood mononuclear cells (PBMC)19. 
HIV-seropositive patients coinfected with GBV-C presented longer 
AIDS-free survival and higher CD4+ T-cell counts, compared with 
HIV-monoinfected patients18 20. Some studies have speculated 
that GBV-C might interfere with HIV and have suggested that 
this flavivirus may have a favorable effect on the course of HIV 
disease18 19. 
GBV-C infection is relatively common and has worldwide 
distribution. A study carried out in the City of São Paulo found 
that 5.1% of the general population were GBV-C positive, while 
5.2-9% of Brazilian blood donors tested positive for GBV-C RNA12. 
Studies evaluating American populations found that 0.8-1.4% were 
positive for GBV-C RNA, whereas 1.8-3.2% were GBV-C infected 
in Europe11. Active GBV-C infection is demonstrated by viremia 
(RNA), while anti-E2 antibodies indicate resolved infection. Thirty 
to 65% of HIV-seropositive patients are positive for anti-E2 GBV-C 
antibodies and, in most cases, viral clearance occurs over time. 
Although simultaneous presence of GBV-C RNA and E2 is rare, 
detection of both of these markers is possible and could indicate 
a transition state17.
Because of similar transmission routes, coinfection between 
GBV-C and HIV is common. Epidemiological studies have indicated 
that 39% of HIV-seropositive patients are viremic for GBV-C and 47% 
present anti-E2 antibodies15. The rates of coinfection in heterosexual 
individuals or injection drug users (IDUs) range from 14 to 17.5%, 
while 17.7% of homosexual men are viremic9. 
The information regarding liver histology is still conflicting 
and no data on triple infection (HIV-HCV-GBV-C) are available. 
Within this context, our study evaluated the effects of GBV-C on 
histopathology, among HIV-HCV coinfected patients, and the 
possible influence of GBV-C on HIV and HCV viral loads. 
The study included 20 HIV-seropositive patients presenting 
chronic coinfection with HCV who underwent liver biopsy at 
Hospital São Paulo, Brazil. Patients were prospectively included 
between May 2006 and May 2007 and the study was approved by 
the Ethics Committee of UNIFESP (CEP 1296/05). 
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The inclusion criteria were as follows: age between 18 and 
70 years; and HIV-seropositive with HCV coinfection. Patients 
were excluded if they had other associated hepatic diseases. The 
technical procedures were carefully explained to all patients. After 
signing a written informed consent, a blood sample was collected 
and the laboratory and virological analyses were carried out.
Demographic data such as gender, age and risk factors 
for HIV and HCV transmission were collected. Data regarding 
medication were also collected. Serum levels of alanine 
aminotransferase (ALT), aspartate aminotransferase (AST) and 
gamma-glutamyltransferase (GGT) were measured and analyzed 
by using the AU640™ Chemistry Immuno-Analyzer (Olympus®). 
Flow cytometric immunophenotyping (FACSCaliburTM, BD, USA) 
was used to determine the CD4 and CD8 T-cell counts. The HCV 
viral load was determined by means of real-time PCR (TaqMan) 
and the lowest detectable limit of HCV viral load was 200 copies/
ml. HCV was genotyped by means of genome sequencing of 
PCR products, followed by phylogenetic analysis. Quantitative 
determination of HIV-RNA was carried out using the branched DNA 
HIV-1 RNA 3.0 assay (Bayer), with a detection range from 50 to 
500,000 copies/ml. GBV-C RNA was detected in plasma samples 
by using an in-house RT-PCR assay2. IgG antibodies against the 
envelope protein E2 of GBV-C were detected using an ELISA assay 
(µPLATE Anti-HGenv, Roche Diagnostics). 
Liver biopsy was indicated for all HCV RNA-positive patients, 
independent of the levels of the liver enzymes for defining the 
prognosis and treatment4. The 20 patients whose biopsies are 
presented in this report were those sequentially performed during 
the study period. The slides were stained with hematoxylin-eosin, 
Masson’s trichrome, Perl’s stain and silver for reticular fibers 
(Gomory’s stain). Liver biopsies with a diagnosis of chronic 
hepatitis or nonspecific reactive hepatitis were semi-quantitatively 
analyzed according to the stage and grade using the criteria 
described by Gayotto et al5. A single pathologist who was unaware 
of the clinical data analyzed all the liver biopsy slides.
The patients were classified into three groups according to 
their GBV-C infection status: HIV-HCV coinfected patients who 
tested positive for anti-E2 antibodies (HIV-HCV-GBV-C E2), triple-
infected patients (HIV-HCV-GBV-C RNA) and patients who were 
neither positive for GBV-C RNA nor positive for anti-E2 antibodies 
(HIV-HCV). Variables were compared between groups by means 
of the Mann-Whitney test, using the SPSS software, version 13.0. A 
significance level of 0.05 (α = 5%) was adopted as significant.
The mean age of the cohort was 43.0 ± 6.2 years; 60% (12/20) 
were men and 40% (8/20) of these had had parenteral exposure. 
The mean length of time with the diagnosis of HIV infection was 
8.3 ± 3.7 years, 85% (17/20) of the cohort were undergoing 
antiretroviral therapy and 85% (17/20) presented undetectable 
HIV RNA levels. The CD4 and CD8 T-lymphocyte counts were 
relatively high, with a mean of 522.8 ± 246.2 cells/mm³ and 912.1 
± 506.6 cells/mm³, respectively. The mean value of ALT was 63.3 ± 
55.0 U/l, AST 48.0 ± 32.5 U/l and GGT 104.7 ± 94.1 U/l. The mean 
HCV viral load among the 20 patients coinfected with HIV-HCV was 
4.56 ± 1.64 log10, while two showed HCV-RNA viral loads below 
the lower limit of detection (< 200 copies/ml). Genotyping data 
demonstrated that HCV genotype 1a was present in 40% (8/20) 
of the cohort and genotype 1b in 20% (4/20).
Among the twenty biopsied patients, 70% (14/20) presented 
negative results for GBV-C (E2 or RNA) markers and 30% (6/20) 
presented at least one marker for GBV-C infection. These included 
15% (3/20) with positive ELISA tests (GBV-C E2) and 15% (3/20) 
who were positive for PCR (GBV-C RNA). The triple-infected 
patients in the biopsied group (HIV-HCV-GBV-C RNA) presented 
undetectable HIV viral loads. 
There were no statistical differences in HCV viral load or 
between any of the liver enzymes levels among the groups, possibly 
because of the limited number of patients. Two of the three 
patients with triple infection presented HCV genotype 1a. Table 1 
shows the characteristics of the cohort and referral criteria for 
classification. The histopathological characteristics of 16 patients 
with nonspecific reactive hepatitis and chronic hepatitis were 
evaluated and are shown in Table 2. The remaining four patients 
presented steatosis (1/20), steatohepatitis (1/20), normal liver 
(1/20) or insufficient material (1/20) and were not evaluated. 
TABlE 1
Histopathological diagnosis of the biopsied patients (n=20).
Histopathological characteristics    n %
Non-specific reactive hepatitis 4 20.0
Chronic hepatitis 
    chronic hepatitis with absent interface hepatitis 4 20.0
    chronic hepatitis with mild interface hepatitis 6 30.0
    chronic hepatitis with moderate interface hepatitis 2 10.0
Steatosis   1 5.0
Steato-hepatitis  1 5.0
Normal liver   1 5.0
Material of narrow size range for histological analysis 1 5.0
We compared the groups of biopsied patients to evaluate 
whether there was any evidence that GBV-C had some beneficial 
effect. As shown in Table 2, our results demonstrated that none of the 
groups presented grade 4 staging or periportal and parenchymatous 
activities. Mild liver disease and lower degree of inflammation were 
observed in the triple-infected group (grades 0-2), histologically 
compared with the HIV-HCV coinfected patients (grades 0-3).
A similar study was carried out by Strauss et al16 among HCV-
GBV-C patients, in which GBV-C RNA was detected in six of the 
22 patients with liver biopsy. Although there were no statistical 
differences between the groups, they observed a lower degree 
of inflammation in the HCV-GBV-C coinfected group and this 
interaction did not demonstrate any reason for more aggressive 
hepatic lesions. Another study on 158 HIV-HCV coinfected patients 
showed a significant association between the presence of GBV-C 
RNA (36%) and lower severity of HCV-related liver disease3.
Despite our small group of patients, we observed that patients 
with active GBV-C replication (RNA) presented a lower degree 
of histological lesions. Further studies with a larger number of 
biopsied HIV-HCV coinfected patients are needed in order to 
provide more conclusive results regarding the effect of GBV-C on 
disease progression among HIV-HCV coinfected patients.
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TABlE 2
Staging and necroinflammatory activity of chronic hepatitis and non-specific reactive 
hepatitis in co-infected patients with HIV-HCV compared with HIV-HCV-GBV-C RNA/
E2 patients.
Histopathological HIV-HCV HIV-HCV-GBV-C RNA HIV-HCV-GBV-C E2
(n=16) (n=10) (n=3) (n=3)
Staging
0 4 0 1
1 5 2 2
2 1 1 0
3 0 0 0
4 0 0 0
Peri-portal activity
0 6 1 1
1 0 0 0
2 2 2 2
3 2 0 0
4 0 0 0
Parenchimatous activity
0 2 0 1
1 3 3 0
2 4 0 2
3 1 0 0
4 0 0 0
HIV: human immunodeficiency virus, HCV: hepatitis C virus, GBV-C: GB virus C, 
RNA: ribonucleic acid.
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